Spruce Biosciences (SPRB) Earnings Analysis
Spruce Biosciences (SPRB) next reports earnings on 2026-08-13, consensus EPS -5.79 USD. Last quarter (2026-03-09) it beat with EPS -9.58 USD vs -12.87 USD est (+25.6%). It has beaten estimates in 6/6 recent quarters (100%). Trailing P/E -1.19.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does SPRB next report earnings?
| Next earnings date | 2026-08-13 |
|---|---|
| Consensus EPS estimate | -5.79 USD |
| Revenue estimate | n/a |
SPRB earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-09 | -9.58 USD | -12.87 USD | +25.6% | Beat |
| 2025-11-10 | -14.58 USD | -15.56 USD | +6.3% | Beat |
| 2025-08-14 | -3.5 USD | -18.05 USD | +80.6% | Beat |
| 2025-04-02 | -0.23 USD | -0.24 USD | +4.2% | Beat |
| 2024-11-11 | -15.79 USD | -20.3 USD | +22.2% | Beat |
| 2024-08-12 | -16.54 USD | -24.81 USD | +33.3% | Beat |
Beat rate: 6/6 (100%) over reported quarters with consensus data.
SPRB valuation and analyst view
| Trailing P/E | -1.19 |
|---|---|
| Trailing EPS | -27.10548 USD |
| Price / book | 1.77 |
| Dividend yield | 0.00% |
| Market cap | 0.06B |
| Analyst consensus | Buy (6 buy / 5 hold / 0 sell) |
| Avg price target | 137.67 USD |
Related research pages
Frequently asked questions
When is Spruce Biosciences (SPRB)'s next earnings date?
Spruce Biosciences is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -5.79 USD.
Did SPRB beat earnings last quarter?
In its 2026-03-09 report, SPRB posted EPS of -9.58 USD versus a -12.87 USD estimate — a beat of 25.6%.
What is SPRB's earnings track record?
Over the last 6 reported quarters with consensus data, SPRB beat estimates 6 times (100%).
What is SPRB's current P/E ratio and EPS?
SPRB trades at a trailing P/E of -1.19 on trailing EPS of -27.10548333775483 USD.
What do analysts rate SPRB?
Analyst consensus is "Buy" across 11 ratings (0 strong buy, 6 buy, 5 hold, 0 sell, 0 strong sell). Average 12-month price target: 137.67 USD.